WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a contract that should produce $150 million a year for 20 years. It just didn’t identify the client.
The Chinese CDMO Monday announced the letter of intent, saying WuXi Vaccines will build a vaccine manufacturing facility that will be able to handle substance and drug product manufacturing and will include quality control labs. It said it has estimated the value of the 20-year manufacturing contract at more than $3 billion.
“Vaccine CDMO is one of the next growth areas for WuXi Biologics,” WuXi Biologics CEO Chris Chen said in a statement.
While WuXi didn’t identify the partner, it offered a couple clues. It said the site will manufacture 100% of the global market of one the partner’s vaccine products, suggesting the vaccines might be intended for use outside China. Most Chinese vaccine makers only produce for the country.
Also, when WuXi Vaccines was formed last year as a joint venture between WuXi Biologics and veterinary vaccine maker Shanghai Hile Bio-Technology, WuXi said in a securities filing the venture was being formed to primarily make cancer vaccines.
Reports in the China media earlier this year said WuXi was in talks with three vaccine developers to make their products in China. But Chen at the time suggested the company might be making a play for the country’s vaccination market after regulatory reactions to scandals by Chinese makers limited their production.
By Eric Palmer
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
